中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2013年
28期
2186-2190
,共5页
林梁%杨定华%黄毓%李湘竑%张庆玲%刘萧%梁鉴坤%钟克波%何华
林樑%楊定華%黃毓%李湘竑%張慶玲%劉蕭%樑鑒坤%鐘剋波%何華
림량%양정화%황육%리상횡%장경령%류소%량감곤%종극파%하화
吲哚胺2_3_双加氧酶%肝细胞肝癌%愈后
吲哚胺2_3_雙加氧酶%肝細胞肝癌%愈後
신타알2_3_쌍가양매%간세포간암%유후
Indolamine-2,3-dioxygenase%Hepatocellular carcinoma%Prognosis
目的 观察吲哚胺2,3双加氧酶(IDO)在肝细胞肝癌(HCC)中的表达,分析其表达与临床病理参数的关系.方法 采用逆转录-聚合酶链反应(RT-PCR)、荧光定量PCR、免疫组化、免疫荧光研究IDO在HCC中的表达.结果 IDO mRNA在癌组织中的表达比相应的非癌组织明显增高(2-△△CT=1.71,P=O.001),△CT值在癌组织中为6.40±2.21,非癌组织中7.17±1.90,正常肝脏组织中7.61±0.93.IDO蛋白主要在癌边缘及癌组织的胞质中表达,而在非癌及肝脏良性病变的正常肝脏组织内则不表达.IDO表达的强弱与术后复发及生存时间、是否发生转移、TNM分期有关(P<0.05);与肝硬化、AFP、病理分化、巴塞罗那分期、性别、年龄、乙肝表面抗原、肿瘤大小及数目无关(P>0.05).结论 IDO的高表达可能会影响HCC患者的愈后.
目的 觀察吲哚胺2,3雙加氧酶(IDO)在肝細胞肝癌(HCC)中的錶達,分析其錶達與臨床病理參數的關繫.方法 採用逆轉錄-聚閤酶鏈反應(RT-PCR)、熒光定量PCR、免疫組化、免疫熒光研究IDO在HCC中的錶達.結果 IDO mRNA在癌組織中的錶達比相應的非癌組織明顯增高(2-△△CT=1.71,P=O.001),△CT值在癌組織中為6.40±2.21,非癌組織中7.17±1.90,正常肝髒組織中7.61±0.93.IDO蛋白主要在癌邊緣及癌組織的胞質中錶達,而在非癌及肝髒良性病變的正常肝髒組織內則不錶達.IDO錶達的彊弱與術後複髮及生存時間、是否髮生轉移、TNM分期有關(P<0.05);與肝硬化、AFP、病理分化、巴塞囉那分期、性彆、年齡、乙肝錶麵抗原、腫瘤大小及數目無關(P>0.05).結論 IDO的高錶達可能會影響HCC患者的愈後.
목적 관찰신타알2,3쌍가양매(IDO)재간세포간암(HCC)중적표체,분석기표체여림상병리삼수적관계.방법 채용역전록-취합매련반응(RT-PCR)、형광정량PCR、면역조화、면역형광연구IDO재HCC중적표체.결과 IDO mRNA재암조직중적표체비상응적비암조직명현증고(2-△△CT=1.71,P=O.001),△CT치재암조직중위6.40±2.21,비암조직중7.17±1.90,정상간장조직중7.61±0.93.IDO단백주요재암변연급암조직적포질중표체,이재비암급간장량성병변적정상간장조직내칙불표체.IDO표체적강약여술후복발급생존시간、시부발생전이、TNM분기유관(P<0.05);여간경화、AFP、병리분화、파새라나분기、성별、년령、을간표면항원、종류대소급수목무관(P>0.05).결론 IDO적고표체가능회영향HCC환자적유후.
Objective To explore the expressions of indoleamine 2,3-dioxygenase (IDO) in hepatocellular carcinoma and analyze its relationship with clinicopathological parameters.Methods Quantitative real-time polymerase chain reaction (PCR),fluorogenic quantitative PCR,immunohistochemical and immunofluorescence were used to detect the expression of indoleamine 2,3-dioxygenase in hepatocellular carcinoma.Results The IDO mRNA expression in cancerous tissues increased markedly than that in the corresponding non-cancerous tissues (2-△△CT =1.71,P =0.001).The immunohistochemical and immunofluorescence results showed that IDO protein was expressed in cytoplasm of hepatocellular carcinoma and tumor-surrounding tissues.But there was no expression in normal liver tissues from benign hepatic lesions and corresponding non-cancerous tissues.An over-expression of IDO protein was detected in 43 patients(48.3%),a low expression in 25 (28.1%) and no expression in 21 (23.6%).Relationship between IDO expression and clinicopathological parameters:an over-expression of IDO in HCC was associated with recurrence,survival time,metastasis and TNM stage (P < 0.05),but not associated with patient's cirrhosis,AFP level,histological differentiation type,Barcelona clinic liver cancer stage,gender,age,HbsAg positivity,number of tumors and tumor size (P > 0.05).Conclusion An overexpression of IDO in HCC patients may affect patient prognosis.